Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Seong Hee KangHyeki ChoEun-Ju ChoJeong-Hoon LeeSu Jong YuYun Joon KimNam-Joon YiKwang-Woong LeeKyung-Suk SuhJung Hwan YoonPublished in: Journal of Korean medical science (2018)
Sorafenib may be beneficial in patients with post-transplant HCC recurrence.
Keyphrases